Citius Oncology annual net income
2021
2022
2022
2023
2023
2024
2025
Citius Oncology Net Income Growth & History (CTOR)
Citius Oncology's net income was −$24.8M for fiscal 2025.
View full Citius Oncology company overviewCitius Oncology annual net income history
| Fiscal year | Period ended | Net income | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | −$24.8M | −$3.6M | — |
| 2024 | 2024-09-30 | −$21.1M | −$8.5M | — |
| 2023 · Dec 31 | 2023-12-31 | $2.4M | $2.0M | +535.30% |
| 2023 · Sep 30 | 2023-09-30 | −$12.7M | −$7.3M | — |
| 2022 | 2022-12-31 | $380,811 | $390,924 | — |
| 2022 | 2022-09-30 | −$5.4M | — | — |
| 2021 | 2021-12-31 | −$10,113 | — | — |
Citius Oncology quarterly net income
Q2.21
Q1.23
Q2.23
Q4.23
Q4.23
Q1.24
Q2.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Net income | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | −$8.9M | −$3.6M | — |
| Q2 2026 | 2026-03-31 | −$26.6M | −$18.9M | — |
| Q1 2026 | 2025-12-31 | −$5.5M | $1.1M | — |
| Q4 2025 | 2025-09-30 | −$5.0M | $1.8M | — |
| Q3 2025 | 2025-06-30 | −$5.4M | −$597,106 | — |
| Q2 2025 | 2025-03-31 | −$7.7M | −$2.9M | — |
| Q1 2025 | 2024-12-31 | −$6.7M | −$1.9M | — |
| Q4 2024 | 2024-09-30 | −$6.8M | −$7.0M | — |
| Q2 2024 | 2024-06-30 | −$4.8M | −$5.4M | — |
| Q1 2024 | 2024-03-31 | −$4.8M | −$5.4M | — |
| Q4 2023 | 2023-12-31 | −$4.7M | — | — |
| Q4 2023 · Sep 30 | 2023-09-30 | $157,943 | — | — |
| Q2 2023 | 2023-06-30 | $616,296 | — | — |
| Q1 2023 | 2023-03-31 | $611,725 | — | — |
| Q2 2021 | 2021-06-30 | −$724 | — | — |
Citius Oncology net income trends
Between the periods ended 2021-12-31 and 2025-09-30, Citius Oncology's net income decreased from −$10,113 to −$24.8M, a change of −$24.8M. The latest reported quarter, Q3 2026, shows −$8.9M.
About the metric
What net income means
Net income is a company’s bottom-line profit or loss after operating costs, interest, taxes, and other reported income and expenses. It shows how much of a company’s revenue ultimately remained as earnings, or how large its loss was, during a fiscal period.
Calculation and source
SEC-reported net income
TickerStat standardizes consolidated net income or profit and loss reported in company SEC filings for aligned fiscal periods. It is not adjusted earnings, an analyst estimate, or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Citius Oncology source filings ↗Community posts
Citius Oncology’s wholesaler shipments rise sharply while institutional orders grow modestly
Citius Oncology ($CTOR) reported preliminary sales of 792 Lymphir units to US wholesalers for its fiscal fourth quarter of 2026, up 120% from 360 in the preceding quarter. Separately, prescribing centers ordered 950 vials from wholesalers, ...
